Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
rVWF (Veyvondi) With or Without Advate in Pediatric Severe von Willebrand Disease
2023-509769-18-00Phase 3Completed
- Sponsor
- Baxalta
- Start
- Mar 2017
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 8
01
Overview
Phase 3, open-label, single-arm trial of vonicog alfa in von Willebrand disease (VWD), sponsored by Baxalta. Started Mar 2017; status: completed.
02
Drugs
vonicog alfa
03
Conditions
von Willebrand disease (VWD)
Beyond the preview
Go deeper on 2023-509769-18-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-509769-18-00.